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Abstract
Fixed, paraffin-embedded (FPE) tissues are a potentially rich resource for studying the role of NOTCH1 in cancer
and other pathologies, but tests that reliably detect activated NOTCH1 (NICD1) in FPE samples have been lacking.
Here, we bridge this gap by developing an immunohistochemical (IHC) stain that detects a neoepitope created by the
proteolytic cleavage event that activates NOTCH1. Following validation using xenografted cancers and normal
tissues with known patterns of NOTCH1 activation, we applied this test to tumors linked to dysregulated Notch
signaling by mutational studies. As expected, frequent NICD1 staining was observed in T lymphoblastic leukemia/
lymphoma, a tumor in which activating NOTCH1 mutations are common. However, when IHC was used to gauge
NOTCH1 activation in other human cancers, several unexpected findings emerged. Among B cell tumors, NICD1
staining was much more frequent in chronic lymphocytic leukemia than would be predicted based on the frequency of
NOTCH1 mutations, while mantle cell lymphoma and diffuse large B cell lymphoma showed no evidence of NOTCH1
activation. NICD1 was also detected in 38% of peripheral T cell lymphomas. Of interest, NICD1 staining in chronic
lymphocytic leukemia cells and in angioimmunoblastic lymphoma was consistently more pronounced in lymph nodes
than in surrounding soft tissues, implicating factors in the nodal microenvironment in NOTCH1 activation in these
diseases. Among carcinomas, diffuse strong NICD1 staining was observed in 3.8% of cases of triple negative breast
cancer (3 of 78 tumors), but was absent from 151 non-small cell lung carcinomas and 147 ovarian carcinomas.
Frequent staining of normal endothelium was also observed; in line with this observation, strong NICD1 staining was
also seen in 77% of angiosarcomas. These findings complement insights from genomic sequencing studies and
suggest that IHC staining is a valuable experimental tool that may be useful in selection of patients for clinical trials.
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Introduction
Notch receptors participate in a conserved signaling pathway
that regulates many cellular phenotypes, including cell fate, cell
proliferation, and cell survival (for review, see [1]). Mammals
possess four Notch genes (NOTCH1-4), each with distinct
patterns of expression and different knockout phenotypes in
mice. Canonical signaling through all four receptors relies on a
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series of ligand-dependent proteolytic cleavages, the last of
which is carried out by a multisubunit protease called gamma-
secretase, which cleaves Notch receptors within the inner half
the receptor’s transmembrane domain. This liberates the Notch
intracellular domain, NICD, which translocates to the nucleus
and forms a short-lived transcriptional activation complex.
Outcomes produced by Notch signaling in normal cells vary
dramatically with cellular context, presumably because
epigenetic patterning of genomes leads to varied effects of
NICD on transcriptional outputs. Genotypic data from humans
and experimental results from mice indicate that NOTCH1 also
has varied roles in cancer, acting as either an oncogene or a
tumor suppressor gene depending on cellular context. Gain-of-
function mutations of NOTCH1 are common in T lymphoblastic
leukemia/lymphoma (T-LL) [2,3], and have also been described
in subsets of chronic lymphocytic leukemia (CLL) [4–6], mantle
cell lymphoma (MCL) [7], diffuse large B cell lymphoma [8],
peripheral T cell lymphoma (PTCL) [9], breast cancer [10], and
non-small cell lung cancer (NSCLC) [11]. These activating
mutations include diverse point substitutions, deletions, and
translocations that produce ligand-independent NOTCH1
proteolysis and activation, as well as mutations that remove a
C-terminal PEST degron domain and thereby stabilize NICD1.
In addition, data emerging from deep sequencing of cancer
genomes has identified frequent mutation of genes encoding
Notch pathway components in high-grade ovarian serous
carcinomas [12], although the functional consequences of
these mutations on Notch signaling is uncertain. There is also
evidence that NOTCH1 has important functional roles in
endothelium and other stromal components that may contribute
to the malignant behavior of cancers [13,14]. Conversely, loss-
of-function mutations distributed over a large part of the
NOTCH1 locus are common in squamous cell carcinomas of
the skin [15] and head and neck [16,17] and also occur in a
smaller subset of squamous cell carcinomas of the lung
[15,18]. Similarly, loss of notch1 function in vascular
endothelium leads to angiosarcoma-like proliferations in mice
[19,20].
There is interest in therapeutic targeting of NOTCH1 in
cancers in which it has an oncogenic role with antagonists such
as inhibitory antibodies and gamma-secretase inhibitors (GSI)
[21]. Ideally, such trials would focus on treatment of patients
whose tumors show evidence of ongoing NOTCH1 activation.
Given the large size of the NOTCH1 locus and the diversity of
genetic aberrations that produce ligand-independent activation
of NOTCH1 or stabilize NICD1, genetic screening for
oncogenic NOTCH1 alterations is challenging, particularly
when working with archival FPE samples. Moreover, it is
suspected that ligand-mediated NOTCH1 activation also
contributes to tumor cell growth and survival, and such tumors
would go undetected by genetic screening.
An ideal biomarker test would detect NICD1 within tumor
cells directly, regardless of the underlying mechanism of
NOTCH1 activation. To this end, we developed a robust,
specific immunohistochemical (IHC) staining method that
detects NICD1 in archival samples. The test relies on a
commercial rabbit monoclonal antibody, previously used only in
Western blot analyses, that is specific for a neoepitope in
NICD1 created by gamma-secretase-mediated proteolysis of
NOTCH1, the event that triggers NOTCH1 signaling. Following
optimization and validation of the test using cancer xenografts
bearing diverse NOTCH1 aberrations and normal tissues, we
screened a large series of human cancers of unknown
NOTCH1 mutational status for activated NOTCH1. Most T-LLs
and CLLs showed evidence of ongoing NOTCH1 activation, as
did many peripheral T cell lymphomas and a small subset
triple-negative breast cancers. Activation of NOTCH1 was also
detected in a majority of angiosarcomas, in line with the
observation that NICD1 is readily detectable in normal
endothelial cells within tumor stroma. By contrast, little or no
NOTCH1 activation was observed in mantle cell lymphoma,
diffuse large B cell lymphoma, non-small cell lung cancers, and
ovarian carcinoma. These findings indicate that NOTCH1
activation among B cell tumors is both more sharply restricted
to and more prevalent in CLL than would be predicted from
prior genotypic data, raise questions about the proposed tumor
suppressive role for NOTCH1 in vascular neoplasms, and
suggest that IHC testing for NICD1 can be used to select
patients for clinical trials of Notch pathway inhibitors,
particularly those involving patients with tumors such as triple-
negative breast cancer, in which NOTCH1 activation is
confined to a small subset of tumors.
Materials and Methods
Use of Human Tissues
Human tissues specimens were approved for use by
Institutional Review Boards as follows. All tissues involved by
lymphoid neoplasms (save one) were collected and used
without informed consent under Brigham and Women’s
Hospital IRB protocol 2010-P002736. A non-small cell lung
carcinoma microarray was constructed with tissues obtained
from patients without consent under Brigham and Women’s
Hospital IRB protocol 2006-P001929. A serous ovarian cancer
microarray was constructed with tissues obtained from patients
without consent under Brigham and Women’s Hospital IRB
protocol 2006-P000321. An angiosarcoma microarray was
constructed with tissues obtained from patients without
informed consent under the University of Texas M. D.
Anderson Cancer Center IRB protocol LAB04-0890. In each of
these instances, the studies were granted waivers of consent
on the following bases: 1) samples were gathered
retrospectively from pathology archives and resulted from
routine surgical procedures performed for diagnostic purposes;
2) patient identities were anonymized and completely delinked
from unique identifiers; and 3) there was no risk to the
participants (only anonymized tissues were used). One T-
lymphoblastic lymphoma sample collected as part of a trial of
the Merck GSI MK-0752 was used with the written informed
consent of the affected patient under Dana Farber/Partners
Cancer Center protocol 2004-P002170. A breast cancer
microarray containing triple negative tumors (negative for
estrogen receptor, progesterone receptor, and HER2
amplification) was constructed with tissues obtained from
patients who provided written informed consent under Dana
Farber Cancer Institute IRB protocol 93-085.
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Use of Mice in Xenograft Studies
REC-1 and KOPT-K1 cell subcutaneous xenograft studies
were performed under Dana Farber Cancer Institute IACUC
protocol 04-111. HCC1599, HCC1587, and MB-157 cell
subcutaneous xenograft studies were performed under a
protocol approved by the IACUC at Merck Oncology. Animal
work was conducted according to NIH guidelines. All xenograft-
bearing animals were monitored daily by veterinary staff for
abnormal behaviors/conditions that might require attention to
minimize suffering. Animals were sacrificed by CO2
asphyxiation per recommendations of the American Veterinary
Medical Association. All animals were maintained in CO2 for a
minimum of 5 minutes following cessation of respiratory
motions.
Cell lines
Cell lines were obtained from the American Tissue Culture
Collection (REC-1, MAVER-1, HCC1599, HCC1587, and
MB-157 cells) or the Leibniz-Institute DSMZ-German Collection
of Microorganisms and Cell Lines (KOPT-K1).
Test development and validation studies
These studies relied on: 1) cell lines with mutations in
NOTCH1 that produce either gain or loss of NOTCH1 function,
that were grown as xenografts in mice; 2) normal human
squamous mucosae and thymus, in which the anatomic
distributions of cells with activated NOTCH1 are known; and 3)
a primary human T-ALL of known NOTCH1 genotype
(described below). Xenografted cell lines and associated
NOTCH1 genotypes are given in Table 1. All xenografted
tumors were fixed in a phosphate buffered solution containing
10% formalin or 4% paraformaldehyde (squamous cell
carcinomas) and embedded in paraffin, and were retrieved
from the tissue archives of individual laboratories in which
xenograft studies were undertaken as part of other studies.
Bones were decalcified following formalin fixation using RDO
Rapid Decalcification Solution (Sigma, St. Louis, MO).
Archival human cancer samples
All FPE samples were used following approval of institutional
review boards (see ethic statements). A primary T-ALL sample
known to bear activating mutations in NOTCH1 was collected
as part of a clinical trial of the gamma-secretase inhibitor
MK-0754 in patients with relapsed/refractory T-ALL [22].
Archival “discarded” T-LL, CLL, MCL, angiosarcoma, and
normal tissue samples were selected from the paraffin-
embedded tissues archives of Brigham and Women’s Hospital
based solely on the availability of tissue fixed in 10% formalin
or in B+, a buffered fixative containing 3.7% formaldehyde and
zinc chloride that is widely used for tissues involved by
lymphoid neoplasms. FPE non-small cell lung cancer [23],
diffuse large B cell lymphoma [24], angiosarcoma [25], and
ovarian cancer [26] specimens were studied by staining
previously described tissue microarrays. A new tissue
microarray containing a set of 78 triple negative breast cancers
was assembled as follows. Archival formalin-fixed, paraffin-
embedded breast cancers were collected and best blocks and
best areas for coring were identified and selected by a breast
pathologist (DD). Results of immunohistochemical studies for
estrogen (ER) and progesterone receptor (PR) and HER2 and
FISH assay results for HER2 were extracted from pathology
reports. Seventy-eight triple negative (ER/PR/HER2 negative)
invasive breast cancers were identified with adequate tumor
tissue for tissue microarray (TMA) construction, which was
carried out in the Dana Farber/Harvard Cancer Center Tissue
Microarray Core Facility. Three 0.6 mm cores were taken from
marked areas and placed into a recipient block using a manual
arrayer (Beecher Instruments).
Immunohistochemistry
Standard 4-micron paraffin embedded tissue sections were
stained using the Ventana Benchmark XT platform (Ventana
Medical Systems, Inc., Tucson, AZ.) with extended heat-
induced epitope retrieval (CC1 Buffer). Slides were incubated
for 1hr at room temperature with anti-NICD1 rabbit monoclonal
antibody (clone D3B8, catalog #4147, Cell Signaling
Technology, Beverly, MA; final concentration, 8.5microgram/
mL). Signals were then amplified (Ventana Amplification Kit,
#760-080) and visualized (Ventana Ultraview Universal DAB
detection kit, #760-500) per the manufacturer’s instructions. All
staining runs included two positive control samples (REC-1 cell
xenograft and tonsillar mucosa). Scoring was performed by two
pathologists (MJK, JCA). Staining results were also reviewed
with pathologists with subspecialty expertise in
hematopathology (MJK, JCA, GP, DD, EAM, EFM), lung
pathology (LC), gynecologic pathology (MH), breast pathology
(DD), and soft tissue pathology (JH, AL), all of whom also
contributed to case selection.
Table 1. Cancer xenografts and associated gain-of-function
mutations in NOTCH1.
Cell Line Tumor Type
NOTCH1
Mutation
Effect on
NOTCH1
Signaling Reference
KOPT-K1 T-LL L1600P/del(P)* Gain [3]
REC-1 MCL del(ECN1)/del(P)* Gain this paper/ [7]
MAVER-1 MCL None N.A. [7]
HCC1599 BreastCarcinoma del(ECN1) Gain [10]
MB-157 BreastCarcinoma del(ECN1) Gain Unpublished data
HCC1587 BreastCarcinoma None N.A. [10]
* X/Y indicates paired mutations created by aberrations in cis in the same
NOTCH1 allele
del(ECN1) indicates the present of a deletion that removes the coding sequence
for the extracellular domain of NOTCH1
del(P) indicates the presence of frameshift or stop codon mutations that remove
the C-terminal NOTCH1 PEST degron domain
T-LL, T lymphoblastic leukemia/ lymphoma; MCL, mantle cell lymphoma;
N.A., not applicable
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NOTCH1 sequencing
DNA was prepared from fresh-frozen samples using the
QiaAmp DNA Mini kit (Qiagen, Valencia, CA). Sanger
sequencing of NOTCH1 mutational hotspots in a case of T-
lymphoblastic lymphoma was performed as described [3];
sequencing traces with analyzed with Mutation Surveyor
Software (Softgenetics, State College, PA). Deep sequencing
of NOTCH1 mutational hotspots was performed as follows.
Primers were designed and validated by Fluidigm (Fluidigm
Corporation, San Francisco, CA) for exons 25-28 and 34 of
NOTCH1 per recommended guidelines for Roche Titanium
sequencing (Roche, Mannheim, Germany). A total of 2304
amplicons representing 48 unique samples amplified with 48
target specific primer pairs were generated in each sequencing
run. Each primer included sample-specific Fluidigm 454 bar
code primer and adapter sequences. Reactions contained
50ng genomic DNA, forward and reverse tagged amplification
primers (1microM), forward and reverse bar code primers
(400nM), 1x Access Array Loading Reagent, 1x FastStart High
Fidelity Reaction Buffer, 4.5mM MgCl2, 5% DMSO, 0.05U
FastStart High Fidelity Enzyme Blend and PCR-grade
nucleotide mix (200microM, Roche). Thermal cycling was
performed on the Fluidigm FC1 Cycler per manufacturer
guidelines. The resultant libraries were harvested and collected
on a microtiter plate, where they were quantified using the
Qubit® dsDNA BR Assay Kit on a Qubit® 2.0 Fluorometer
(Invitrogen, UK). Libraries were normalized and pooled before
purification using Agencourt AMPure XP system (Beckman,
UK) per the manufacturer’s protocol. Library components were
clonally amplified using the GS Junior emPCR Lib-A Kit
(Roche) by inputting 1 molecule of library DNA per capture
bead. Pyrosequencing was performed using the GS Junior
system (Roche/454 Life Sciences).
To selectively detect the codon 2514 del(CT) mutation in
NOTCH1, a pyrosequencing assay was developed. Briefly,
NOTCH1 exon 34 target sequence was amplified in a PCR
containing 30ng of genomic DNA, a biotinylated forward primer
(5'-CTCCTCGCCTGTGGACAA) and a reverse primer (5'-
GGGACGAGCTGGACCACT) using the following cycling
parameters: 94°C x 2 minutes, followed 94°C x 30 seconds,
62°C x 30 seconds, 72°C x 30 seconds for 45 cycles, followed
by a final extension at 72°C for 10 minutes. The PCR
amplification product was captured on streptavidin sepharose
beads, denatured, transferred to a pyrosequencing plate,
annealed to a reverse sequencing primer (5'
CACTGGTCAGGGGACT 3'), and sequenced per a standard
protocol (PyroMark Q96 MD, Qiagen, Germantown, MD). The
decision to use a reverse sequencing primer was based on the
fortuitous presence of a run of 3 G residues immediately 3’ of
the ΔG antisense codon 2514 mutation, which acts to increase
the sensitivity of the assay roughly 3-fold. In line with this
prediction, control studies using the cell line KOPT-K1, a T-LL
cell line with a heterozygous del(CT) codon 2514 mutation [3],
showed reliable detection of this sequence variant when diluted
down to a level of 2.5% mutated alleles with DNA containing
wild type NOTCH1 alleles.
Molecular Characterization of an Intragenic NOTCH1
Deletion in REC-1 cells
5’ rapid amplification of cDNA ends (RACE) was performed
on RNA prepared from REC-1 cells and control DND-41 T-ALL
cells as described [27]. Genomic DNA was isolated from
REC-1 cells using the QIAamp genomic DNA isolation kit
(Qiagen, Valencia, CA). Exon1 sense (5’-
CCTGCTCTGCCTGGCGCTG) and exon 28 (5’-
CCACGAAGAACAGAAGCACA) antisense primers were used
to amplify the intragenic Notch1 deletion from 100ng of
genomic DNA using the Expand Long Template PCR system
(Roche, Branford, CT). The PCR amplification conditions were
94°C x 2 minutes, followed by 94°C x 15 seconds, 60°C x 30
seconds, and 68°C x 45 seconds for 30 cycles, followed by a
68°C extension for 7 minutes. The resulting PCR product was
purified, cloned into the pCR2.1-TOPO plasmid (Invitrogen,
Carlsbad, CA), and Sanger sequenced.
Western Blot Analysis
Whole cell detergent lysates of cell lines prepared as
described [27] were stained for NICD1 (catalog # 4147), total
NOTCH1 (catalog #4380), or actin (catalog #4970) using
antibodies obtained from Cell Signaling Technologies (Beverly,
MA).
Xenograft Studies
REC-1 cells and MAVER-1 cells were inoculated
subcutaneously into 6-week old SCID/beige mice (Charles
River Laboratory, Wilmington, MA) (1x107 cells per mouse) in
30% Matrigel basement membrane matrix (Becton Dickinson,
Franklin Lakes, NJ). Tumor volume was determined by caliper
measurements. When tumors reached a volume of 100-200
mm3, mice were treated with the gamma-secretase inhibitor
diaminobenzidine (DBZ) at 10microM/kg by intraperitoneal
injection or with vehicle (DMSO) for 3 days. Tissues were
harvested 2hr after the last drug dose. KOPT-K1 cells
transduced with a lentivirus that expresses firefly luciferase
were injected by tail vein into NOD/SCID/gamma-chain (NSG)
mice bred at the Lurie Family Imaging Center (Dana Farber
Cancer Institute). Mice were monitored for development of
leukemia by bioluminescence and then treated with DBZ or
DMSO as above. HCC1587 and HCC1599 human breast
cancer cell line xenografts were developed in CB17 mice as
described [10], while MB157 cell line xenografts were
developed in Swiss nu/nu (nude) mice, all at Merck Oncology.
Animal studies were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
Results
Development of an Immunohistochemical Stain for
Activated NOTCH1
Although canonical Notch signaling relies on nuclear
translocation of its intracellular domain (NICD), detection of
nuclear NICD in situ in human tissues has been difficult.
Polyclonal antibodies that detect the neoepitope created at the
Gauging NOTCH1 Activation in Cancer
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amino-terminus of NICD1 by cleavage of NOTCH1 at
conserved site within its transmembrane domain have been
widely used to identify NICD1 in cell lysates, but have not
yielded reliable IHC tests. Recent development of a rabbit
monoclonal antibody against the NICD1 neoepitope
encouraged us to revisit the possibility of using IHC to detect
NICD1 in FPE tissues. To limit run-to-run staining variation and
to enable possible clinical translation, we evaluated staining on
two widely used automated immunostaining platforms, the
Ventana Discovery XT and the Leica Bond. Both performed
similarly, but we noted that staining interpreted as specific (as
per below) appeared stronger on the Ventana platform (data
not shown), which was used for all of the studies reported
herein.
To develop a reliable staining method for NICD1, we made
use of control FPE tissues from mice xenografted with human
tumor cell lines bearing oncogenic NOTCH1 mutations that
result in ligand-independent generation of NICD1 (Table 1).
Tumors studied with gain-of-function NOTCH1 mutations
included a T-LL cell line, KOPT-K1, which has an activating
point substitution in the NOTCH1 negative regulatory region
aligned in cis with a codon 2514 del(CT) mutation that results
in deletion of the C-terminal NOTCH1 PEST degron domain
[3]; the MCL cell line REC-1, which bears a NOTCH1 allele
with a previously uncharacterized activating deletion removing
most of the coding sequence for the NOTCH1 ectodomain
aligned in cis with a nonsense mutation in codon 2428
(described below) that also results in deletion of the C-terminal
PEST degron domain; and two breast cancer cell lines,
HCC1599 and MB-157, which bear NOTCH1 alleles with
deletions that remove most of the NOTCH1 ectodomain coding
sequences ( [10]; and data not shown). Formalin FPE sections
of all four xenografts bearing activating NOTCH1 mutations
showed strong diffuse nuclear reactivity when stained with the
NICD1-specific antibody (Figure 1A–D). Notably, NICD1
staining in KOPT-K1 and REC-1 xenografts was markedly
reduced by treatment of animals with the GSI DBZ (Figure 1E,
F), which blocks the generation of NICD1 ( [3]). In addition, no
NICD1 staining was seen in sections of the MCL cell line
MAVER-1 (Figure 1G), which has wild type NOTCH1 alleles
and is devoid of NICD1 [7], or in the breast cancer cell line
HCC1587 (Figure 1H), which has wild type NOTCH1 alleles
and instead has an activating deletion involving NOTCH2 [10].
To further evaluate the sensitivity of the method and the
stability of the NICD1 neoepitope in archival tissues, we
performed IHC for NICD1 on sections prepared from a T-LL
specimen obtained in the year 2004 from a patient enrolled in a
trial of the Merck GSI MK-0754 [22]. Sanger sequencing of
DNA isolated from this specimen revealed a heterozygous
point mutation that results in a L1574P substitution, as well as
two additional subclonal point mutations aligned in cis with the
L1574P substitution that create L1600P and F1592S
substitutions (Figure 2A). All of these mutations fall in exon 26
of NOTCH1 and correspond to previously characterized gain-
of-function mutations in the NOTCH1 negative regulatory
region [28], a portion of the NOTCH1 ectodomain that must be
intact to keep the receptor in the off-state in the absence of
ligand [29]. Tandem mutations aligned in cis in the NOTCH1
ectodomain have been reported previously [3] and are likely a
manifestation of continued selection for increased NOTCH1
signaling during T-ALL progression. IHC staining of this T-ALL
produced strong diffuse nuclear positivity, suggesting that the
NICD1 epitope detected by the rabbit monoclonal antibody is
stable for a period of years in routinely stored FPE samples
(Figure 2B).
We also noted in sections of xenografted tumors that murine
endothelial cells and scattered stromal cells showed nuclear
reactivity with the NICD1 antibody (best seen in Figure 1G and
H). These observations are in line with data indicating roles for
notch1 in vascular endothelium [30] and peripheral T cells [31],
and suggested that our IHC method can detect physiologic
levels of NICD1. To evaluate this, we stained normal sections
of human squamous mucosa, skin, and thymus (Figure 3).
Prior work has shown that notch1 is transiently activated in
suprabasilar cells in squamous epithelia [32], in which it
promotes cell cycle exit and differentiation [33], an activity that
may contribute to NOTCH1’s tumor suppressive roles in
squamous cell carcinomas of the skin and head and neck. As
expected, NICD1 staining in squamous epithelia was confined
to suprabasilar cells (Figure 3A, B). In thymocytes, notch1
activation rises to a maximum in CD4/CD8 double-negative
cells undergoing beta-selection [34], which are located within
the thymic cortex just deep to the thymic capsule [35]. In prior
work, we noted that cells in this region of the thymus have the
highest level of immunoreactivity with antibodies that recognize
total notch1, without regard to its activation status [36]. As
predicted from the reported pattern of NOTCH1 activation in
thymocytes, NICD1 staining in human thymus was most
prominent in cortical thymocytes lying immediately below the
capsule (Figure 3C, D). These results demonstrate that our
IHC method is sufficiently sensitive to detect physiologic levels
of activated NOTCH1 in at least some normal tissues. To
further explore NOTCH1 activation in normal lymphoid tissues,
staining of tonsil was also carried out. We noted that germinal
centers containing reactive B cells were devoid of
immunoreactivity, whereas surrounding mantle zones showed
weak staining for NICD1 (data not shown).
Detection of NOTCH1 Activation in Archival Cancer
Specimens
Building on these validation studies, we next used IHC to
screen a series of FPE human cancers for evidence of
NOTCH1 activation, focusing on tumor types in which NOTCH1
gain-of-function mutations have been described. We also
studied angiosarcoma, based on the observation that normal
endothelial cells frequently stained positively for NICD1 and
prior studies suggesting that notch1 has a tumor suppressive
function in murine vascular endothelium [19,20]; hence, we
were curious to see if NOTCH1 activation might be lost in
human angiosarcomas. We used NICD1 staining of normal
endothelial cells as an internal control to judge the preservation
of immunoreactivity in the tissues studied. In exploratory
studies, we noted that archival samples fixed in Zenker’s
solution, a mercuric fixative used at our institution to decalcify
bone marrow biopsies, negated NICD1 immunoreactivity in
endothelium. Loss of immunoreactivity was not caused by
Gauging NOTCH1 Activation in Cancer
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decalcification per se, since bone marrow involved by
xenografted KOPT-K1 cells that was fixed in formalin and then
rapidly decalcified with a strong acid retained immunoreactivity
(Figure 1A). Because of this limitation, we confined our studies
to tumors involving soft tissues for which FPE samples were
available. Some lymph nodes involved by CLL samples were
fixed in B+, a fixative that contains formaldehyde and zinc
chloride. Samples fixed in B+ retained NICD1 staining in
normal endothelial cells and thus were included in the analysis.
Results are summarized in Table 2 and are described in the
sections below.
T lymphoblastic leukemia/lymphoma (T-LL)
NOTCH1 gain-of-function mutations occur in roughly 50% to
60% of human T-LL [3] and a high fraction of murine T-LL
models. Consistent with the known incidence of NOTCH1 gain-
of-function mutations in human disease, 8 of 14 T-ALLs
screened (57%) showed diffuse nuclear staining for NICD1
(Figure 4A). In tumors that were negative, little or no staining
was observed. This black and white distinction—diffuse
positivity or no staining—is consistent with the idea that T-LL
falls into two major classes, one in which NOTCH1 is “on” by
virtue of acquired gain-of-function mutations and a second that
is unrelated to NOTCH1 activation and free of NOTCH1
mutations.
Mantle cell lymphoma (MCL)
A recent report identified NOTCH1 exon 34 mutations in 11%
of MCL and in the MCL cell line REC-1, while certain other
MCL cell lines such as MAVER1 were free of NOTCH1
mutations [7]. The high levels of NICD1 in REC-1 cell line
extracts [7] and the intense immunoreactivity of xenografted
REC-1 cells stained for NICD1 suggested that this cell line
might harbor additional mutations leading to ligand-
independent activation of NOTCH1, since exon 34 mutations
affecting the NOTCH1 PEST domain have no effect on NICD1
generation per se [3,28]. The most common mutations leading
to ligand-independent activation of NOTCH1 in human T-LL are
point mutations in the extracellular negative regulatory region,
but sequencing of REC-1 failed to identify mutations in this
Figure 1.  Validation of IHC staining of NICD1 using formalin FPE tumor xenografts.  Sections were stained for NICD1 using
an IHC method that produces a brown nuclear stain and counterstained with hematoxylin. A) KOPT-K1 T-ALL cells. B) REC-1
mantle cell lymphoma cells. C) HCC1599 breast carcinoma cells. D) MB-157 breast carcinoma cells. E, F) KOPT-K1 and REC-1 cell
staining, respectively, in tissues harvested from animals treated with the GSI DBZ. G) MAVER-1 mantle cell lymphoma cells. H)
HCC1587 breast cancer cells. Genotypes of these cell lines are given in Table 1.
doi: 10.1371/journal.pone.0067306.g001
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region [7]. We previously noted that murine T-LLs often have
activating deletions that remove the coding sequences for the
notch1 extracellular negative regulatory region [27], and similar
lesions in human NOTCH1 occur in a subset of human breast
cancers and breast cancer cell lines such as HCC1599 and
MB-157 [10].
We thus asked whether REC-1 cells might harbor a
NOTCH1 deletion leading to expression of an aberrant
NOTCH1 mRNA. Using 5’-rapid amplification of cDNA ends (5’-
RACE), we identified an abnormal transcript consisting of an in-
frame fusion of NOTCH1 exon 1 and exon 28 sequences
(Figure 5A, C). PCR amplification of genomic REC-1 DNA
produced a product with the same sequence (Figure 5B, C),
consistent with the presence of a NOTCH1 deletion created by
Figure 3.  NICD1 staining in normal formalin FPE human
tissues.  A) Oropharyngeal squamous mucosa. B) Skin. C, D)
Thymus.
doi: 10.1371/journal.pone.0067306.g003
Table 2. Summary of NICD1 staining in human FPE cancer
specimens.
Tumor (Number of Cases) NICD1 Staining Results
T-LL (N=14) 57% positive (N=8; all diffusely positive)
CLL (N=52) 89% positive (N=46; 15% diffuselypositive, 74% subset positive)
Peripheral T cell lymphoma (N=55) 38% positive (N=21; 1.8% diffuselypositive, 36% subset positive)
Mantle cell lymphoma (N=53) 0% positive
Diffuse large B cell lymphoma (N=68) 0% positive
Triple negative breast carcinoma
(N=78) 3.8% positive (N=3; all diffusely positive)
Non-small cell lung carcinoma (N=151) 0% positive
Ovarian carcinoma (N=147) 0% positive
Angiosarcoma (N=57) 77% positive (N=44; 47% diffuselypositive, 30% subset positive)
Diffusely positive, ≥80% of cells positive; subset positive, ≤80% of cells positive
Figure 2.  NICD1 staining in an archival human T-LL of known genotype.  A) Identification of activating mutations involving
exon 26 of NOTCH1. Of 24 individual cloned PCR products, 13 gave wild type sequences, 9 showed a mutation producing a L to P
substitution in residue 1574, 1 showed the L1574P mutation in cis with a mutation producing a F to S substitution in residue 1592,
and 1 showed the L1574P mutation in cis with a variant producing a L to P substitution in residue 1600. B) IHC staining for NICD1 in
the same tumor, a formalin-fixed paraffin-embedded biopsy of a mediastinal mass. There is crush artifact, but strong nuclear
staining is seen in intact cells.
doi: 10.1371/journal.pone.0067306.g002
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DNA breaks in exon 1 and exon 28 followed by non-
homologous end joining. Virtual translation of the aberrant
REC-1 transcript produces a membrane-tethered form of
NOTCH1 closely resembling truncated forms of NOTCH1 that
are potent leukemogens in mice [37] and that undergo ligand-
independent cleavage by gamma-scretase to yield NICD1 [38].
In line with this prediction, treatment of REC-1 cells with GSI
led to accumulation of a truncated NOTCH1 protein and
disappearance of NICD1 (Figure 5D).
Based on the findings in REC-1 cells and the report of
NOTCH1 mutations in 11% of MCLs [7], we anticipated that
NICD1 staining would be observed in a significant subset of
MCLs. However, IHC staining in 53 cases of MCL was
uniformly negative, suggesting that NOTCH1 activation and (by
extension, NOTCH1 mutations) were absent from our cohort of
cases, which were diagnosed by experienced
hematopathologists using standard World Health Organization
criteria. In line with the IHC results, deep sequencing of DNAs
prepared from all MCLs for which frozen tissue was available
(N=45) failed to detect any mutations in NOTCH1 exons
encoding the extracellular negative regulatory region (exons
25-27), the gamma-secretase cleavage site (exon 28), or the
C-terminal PEST degron domain (exon 34) (data not shown).
Based on prior structure: function studies [28,39], these exons
span all regions of NOTCH1 that are predicted to potentially
harbor gain-of-function point mutations and small insertions
and deletions. Thus, although activating NOTCH1 mutations
clearly occur in MCL, they may be less common than originally
thought.
Chronic lymphocytic leukemia (CLL)
In contrast to T-LL and MCL, staining for NICD1 in CLL was
both more frequent and more variable. In total, 89% of CLLs
(46 of 52 cases) stained positively for NICD1 in >10% of tumor
cells; of these 33% (17 of 52) stained positively in >50% of
tumor cells, and 15% (8 of 52) showed diffusely positive
staining (defined as staining in >80% of cells). Examples of
diffusely positive cases and subset-positive cases are shown in
Figure 4B and 4C, respectively. From 10% to 18% of CLLs
have been reported to have NOTCH1 gain-of-function
mutations in prior studies [4–6]; thus, the frequency of
NOTCH1 activation as judged by NICD1 staining in our tumor
cohort greatly exceeds what would be expected if activation
were confined to CLLs with NOTCH1 mutations.
To evaluate genotype/phenotype relationships directly, deep
sequencing was performed on all CLL samples evaluated by
NICD1 staining for which fresh-frozen tissue was available
(N=46). Fold coverage of reads in most samples was >100,
Figure 4.  NICD1 immunoreactivity in archival FPE human cancers.  A) T-ALL. B) CLL, diffuse pattern. C) CLL, subset pattern.
D) Adult T-cell leukemia/lymphoma. E) Triple-negative breast carcinoma. F) Angiosarcoma.
doi: 10.1371/journal.pone.0067306.g004
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sufficient to allow detection of minor subclones. We detected
NOTCH1 gain-of-function mutations in 8 of 46 cases (17%), all
in exon 34. Seven corresponded to a del(CT) mutation in
codon 2514 that is highly prevalent in CLL, and one
corresponded to a nonsense mutation in codon 2444 (Figure
6A); mutations at both of these sites result in disruption of the
C-terminal PEST degron domain. Six mutations were present
in dominant clones (defined as >20% mutated reads), whereas
two mutations were present in minor subclones (defined as
<5% mutated reads). All seven codon 2514 del(CT) mutations
were confirmed using a pyrosequencing assay capable of
detecting approximately 2.5% mutated sequences diluted into
wild type DNA; representative pyrosequencing results are
shown in Figure 6B. The NOTCH1 codon 2444 nonsense
mutation was confirmed by repeat deep sequencing of DNA
from two additional frozen pieces of tissue from this case. In
the first piece of tissue analyzed, the codon 2444 mutation was
present in 46% of reads, and in the two additional pieces the
same mutation was present in 33% and 48% of the reads (data
not shown), confirming that this mutation is also real.
We then correlated NOTCH1 activation with NOTCH1
genotype. The fraction of reads with NOTCH1 mutations in a
particular sample was strongly correlated with NICD1 staining
(Figure 7A), in line with the expectation that PEST deletions
should stabilize NICD1 and increase its levels. Cases with
NOTCH1 mutations had significantly more widespread staining
for NICD1 than cases with wild type alleles (Figure 7B, p<0.05);
however, there was substantial overlap between these two
groups of tumors, and some tumors with wild type NOTCH1
alleles were diffusely positive for NICD1 (>80% of cells
positive). We also assessed the relationship between NOTCH1
activation and cytogenetic abnormalities, which are widely used
markers of prognosis in CLL. Prior work showed enrichment for
NOTCH1 mutations in CLLs associated with trisomy 12 [40,41],
suggesting that this group of tumors might have higher levels of
NOTCH1 activation. Among CLLs for which cytogenetic results
Figure 5.  Identification of an activating deletion in NOTCH1 in REC-1 mantle cell lymphoma cells.  A) 5’-RACE products
synthesized from input RNA from REC-1 MCL cells and DND-41 T-ALL cells; the latter have intact NOTCH1 alleles. B) Results of
PCR of genomic REC-1 and DND-41 cell DNA with a NOTCH1 exon 1/exon 28-specific primer pair. C) Sequence of the 5’-RACE
product in A and the genomic PCR product in B. Both showed an in-frame fusion of exon 1 and exon 28 NOTCH1 coding
sequences. D) Cartoon depicting the intragenic NOTCH1 deletion in REC-1 cells and its consequences at the level of NOTCH1
RNA and protein. The red X denotes the position of a frame-shift mutation in exon 34 of NOTCH1. L, leader peptide; TM,
transmembrane domain; R, RAM domain; ANK, ankyrin repeat domain; TAD, transcriptional activation domain. E) Western blot
showing the effect of treatment of REC-1 cells with the gamma-secretase inhibitor (GSI) compound E for 72 hours versus DMSO
control. GSI depletes NICD1 (detected with the NICD1-specific V1744 antibody) and leads to the accumulation of a polypeptide of
the size predicted by virtual translation of the aberrant NOTCH1 mRNA. Total NOTCH1 was detected with a polyclonal antibody
raised against the NOTCH1 TAD.
doi: 10.1371/journal.pone.0067306.g005
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were available, however, we did not observe any significant
difference in NICD1 staining between tumors with trisomy 12,
del(13q), or del(17p) (Figure 7C). The most notable
observation was low NICD1 positivity in tumors associated with
del(11q) relative to other cytogenetics subtypes (p<0.02).
Frequent activation of NOTCH1 in CLLs with wild type
NOTCH1 alleles suggests that microenvironmental factors
(e.g., Notch ligands) mediate NOTCH1 activation in this
disease. Little is known about Notch ligand expression in lymph
nodes, and reliable IHC staining methods for the full set of
Notch ligands (Jagged1, Jagged2, Delta-like-1, Delta-like-3,
Figure 6.  NOTCH1 mutations in CLL.  A) Position of
NOTCH1 mutations, superimposed on a cartoon showing the
NOTCH1 protein. NRR, negative regulatory region; RAM, RAM
domain; ANK, ankyrin repeat domain; TAD, transcriptional
activation domain; PEST, degron domain. B) Representative
confirmatory pyrosequencing results in CLL cases positive by
deep sequencing for the NOTCH1 codon 2514 del(CT)
mutation. Results for a case with wild type codon 2514
sequences is shown in the upper panel. The lower two panels
are cases in which deep sequencing revealed high (54.1%) or
low numbers of mutated reads (3.3%). Reverse-sequences of
the wild type (WT) and mutant (MUT) del(CT) alleles are shown
for reference. “E” corresponds to the addition of enzyme to the
reaction chamber, while “S” corresponds to the addition of the
substrate. In this sequencing by synthesis assay, nucleotides
are added to the reaction chamber sequentially in the order
shown. Nucleotide incorporation releases pyrophosphate,
which catalyses a reaction in which the number of photons
produced is proportional to the number of nucleotides
incorporated. The codon 2514 del(CT) mutation causes the
appearance of a new signal corresponding to the incorporation
of 3 G residues.
doi: 10.1371/journal.pone.0067306.g006
and Delta-like-4) have yet to be developed, limiting our ability
to directly assess the possible involvement of ligands.
However, several “experiments of nature” in our tumor set point
to a role for intranodal factors in NOTCH1 activation. In 13 of
the CLL cases studied, tumor cells extended beyond the lymph
node capsule into perinodal soft tissue. In 12 of these 13
cases, we noted that NICD1 staining was much weaker in
tumor cells in perinodal soft tissue than it was within tumor cells
in the immediately adjacent lymph node, including one case
associated with a the NOTCH1 codon 2514 del(CT) in 35% of
sequencing reads (Figure 8A). In addition, the case with a
NOTCH1 codon 2444 nonsense mutation in 42% of
sequencing reads subsequently recurred as a tumor with wild
type NOTCH1 alleles (Figure 8B, C). The original mutated
sample showed evidence of transformation to a more
aggressive histologic grade as judged by the presence of
frequent large cells, a feature associated with NOTCH1
mutations in a prior report [5], whereas the later lymph node
biopsy showed only a few scattered large cells. NICD1 staining
was somewhat stronger in the earlier tumor with mutated
NOTCH1, but both biopsies showed diffusely positive NICD1
staining. These observations are consistent with past work
showing that exon 34 mutations producing C-terminal PEST
domain deletions have no effect on receptor activation per se
[3,28]; thus, they are only selected for in contexts in which
there is already ongoing NOTCH1 activation, which may be
caused by mutations in exons 25-28 (apparently absent in CLL)
or by ligand-mediated NOTCH1 activation.
Diffuse large B cell lymphoma
Mutations in NOTCH1 have been reported in a minor subset
of diffuse large B cell lymphoma [8]. However, staining of a
tissue microarray containing 68 well-characterized diffuse large
B cell lymphomas revealed no NICD1 positive tumors (Table
2). Thus, NOTCH1 activation is uncommon in diffuse large B
cell lymphoma.
Adult T-cell leukemia/lymphoma and other peripheral T
cell lymphomas
Staining of a diverse collection of peripheral T cell
lymphomas, subclassified by World Health Organization
criteria, revealed NICD1 positivity in 21 of 55 cases (38%;
Table 3), including diffuse nuclear positivity in 1 case of adult T
cell leukemia/lymphoma (Figure 4D). Also noted was a variable
pattern of NICD1 immunoreactivity in 12 of 14 cases (86%) of
angioimmunoblastic lymphoma, a T cell lymphoma derived
from follicular T helper cells (Figure 9). As with CLL, NICD1
staining was diminished in angioimmunoblastic lymphoma cells
in extranodal soft tissues, suggesting that NICD1 production is
also stimulated in this tumor-type by factors in the nodal
microenvironment (Figure 9).
Triple-negative breast cancer
Activating deletions in either NOTCH1 or NOTCH2 have
been identified in a minority of breast cancers, most of which
are triple-negative (ER/PR/HER2 negative) tumors [10].
Staining of a tissue microarray containing 78 triple negative
breast cancers for NICD1 identified 3 tumors (3.8%) with strong
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diffuse nuclear staining (Figure 4E), a pattern similar to that in
xenografted breast cancer cell lines with activating deletions of
NOTCH1 (Figure 1C and D).
Non-small cell lung cancer (NSCLC) and Ovarian
Carcinoma
None of 151 NSCLCs or 147 ovarian serous carcinomas had
detectable NICD1 staining (Table 2). All cases scored
demonstrated staining for NICD1 in vascular endothelium,
indicating that lack of staining in tumor cells was unlikely to
have resulted from loss of tissue immunoreactivity. Thus,
despite reports of NOTCH1 PEST domain mutations in lung
cancer [11] and NOTCH3 amplification and acquired mutations
in genes encoding other NOTCH pathway signaling
components in ovarian cancer [12,42], NOTCH1 activation
does not appear to be common in either of these tumors.
Angiosarcoma
An initial screen of 3 well-differentiated angiosarcomas of the
scalp revealed diffuse NICD1 positivity in all 3 tumors (Figure
4F), prompting us to study NOTCH1 activation in an arrayed
collection of 54 additional angiosarcomas. Overall, these
studies revealed diffuse or focal positive staining for NICD1 in
77% (44 of 57) of angiosarcomas (Table 2). In general, well-
differentiated vasoformative tumors showed more diffuse and
stronger staining than tumors with epithelioid morphologies or
solid growth patterns, both of which are associated with more
aggressive behavior.
Discussion
The method described here for detecting NICD1 in FPE
tissues should find wide utility in evaluating NOTCH1 activation
in clinical samples and experimental models of human disease.
Figure 7.  Relationship of NICD1 staining, NOTCH1 genotype, and karyotype in CLL.  A) Correlation between the fraction of
mutated NOTCH1 exon 34 reads and NICD1 staining. B) NICD1 staining in CLLs with and without mutated NOTCH1 alleles. Filled
squares correspond to CLLs with the NOTCH1 codon 2514 del(CT) mutation; black squares are tumors with a “high” fraction
(>20%) of mutated reads, while gray squares are tumors with a “low” fraction (<5%) of mutated reads. The open square
corresponds to a CLL with a nonsense mutation in codon 2444. C) Relationship of NICD1 staining to CLL karyotype. Open squares
correspond to tumors with NOTCH1 mutations.
doi: 10.1371/journal.pone.0067306.g007
Figure 8.  Salient observations from archival CLL biopsies stained for NICD1.  A) Loss of NICD1 positivity in extranodal tumor.
This case was associated with a NOTCH1 codon 2514 del(CT) mutation (35% of sequencing reads). E, extranodal fibrofatty tissue;
C, lymph node capsule; N, lymph node. B, C) NICD1 staining in sequential biopsies involved by CLL with (B) and without (C) the
NOTCH1 codon 2444 nonsense mutation. The specimen in (B) was associated with 42% mutated sequencing reads; no mutated
reads were detected in the subsequent biopsy shown in (C).
doi: 10.1371/journal.pone.0067306.g008
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It relies on a commercial rabbit monoclonal antibody and can
be performed using standardized reagents on widely used
automated staining platforms. The antibody detects a
neoepitope at the amino terminus of NICD1 that is created by
gamma-secretase cleavage of human NOTCH1 and murine
notch1, and which appears to be stable in FPE samples stored
routinely for a decade or more. We anticipate that this IHC
stain should be useful in a number of contexts, including: i)
studies using tissue archives to explore the role of NOTCH1 in
various neoplastic and non-neoplastic disorders; ii) selection of
patients for trials of gamma-secretase inhibitors (GSIs) [21], the
lead Notch pathway antagonists being tested in cancer
patients, particularly trials involving diseases such as triple-
negative breast cancer in which NOTCH1 activation is confined
to a small subset of tumors; and iii) judging the efficacy of
NOTCH1 antagonists in experimental models and in patients.
Staining for NICD1 may also prove useful in identifying tumors
with NOTCH1 loss-of-function mutations, which are present in
a subset of squamous cell carcinomas.
The IHC test that we described has certain limitations.
Decalcification of bone marrow with some agents (e.g.,
Zenker’s solution) seems to negate immunoreactivity, based on
staining of T-ALLs for which both soft tissue samples and
involved bone marrow were available (data not shown). In
addition, the assay is specific for NOTCH1, and therefore
cannot be used to assess activation of other NOTCH receptors,
which have been implicated in certain cancers. Specifically,
activating NOTCH2 mutations have been identified in marginal
zone B-cell lymphoma [43–45] and diffuse large B-cell
lymphoma [8], and biochemical analyses have detected
activation of NOTCH2 as well as NOTCH1 in CLL [46,47].
Similarly, amplification of NOTCH3 has been described in
ovarian cancers [42,48]. It may be possible to overcome this
limitation by developing IHC stains for activated NOTCH2-4,
which is feasible in principle since the neoepitopes created by
gamma-secretase cleavage of NOTCH1-4 are unique. Finally,
a role for NOTCH1 in maintenance of cancer stem cells has
been proposed in some tumors [49–52]; if such cells are rare,
assessment of NICD1 in bulk tumor cell populations may
underestimate the contribution of NOTCH1 to the malignant
phenotype.
In addition to a small subset of breast cancers and (as
expected) more than half of T-LLs, our screen of human
cancers indicates that NOTCH1 activation is prevalent in CLL
and also occurs in a subset of peripheral T cell lymphomas and
a high fraction of angiosarcomas. An unexpected finding,
based on prior results of genomic sequencing studies, was the
much more widespread activation of NOTCH1 in CLL than in
other two other B cell tumors, mantle cell lymphoma [7] and
diffuse large B cell lymphoma [8]. NOTCH1 activation in CLL is
not confined to tumors with NOTCH1 mutations and appears to
be augmented by factors expressed in the nodal
microenvironment. These findings raise questions about how
best to gauge and target NOTCH1 activation in CLL patients
who are being considered for treatment with Notch pathway
inhibitors. It would be desirable to be able to stratify patients
based on analysis of circulating CLL cells, but our findings
raise several questions about analyses conducted on
peripheral blood. On the one hand, the loss of NICD1
immunoreactivity in CLL cells in soft tissues adjacent to lymph
nodes suggests that the levels of NOTCH1 activation differ in
CLL cells in different microenvironments within an individual
patient. It will be of interest to compare levels of NOTCH1
activation in lymph nodes and peripheral blood cells obtained
from patients at the same time point. On the other hand, it
appears that NOTCH1 mutational analysis may underestimate
the involvement of NOTCH1 in CLL, based on the presence of
readily detectable NOTCH1 activation in the nodal
microenvironment in cases with wild type NOTCH1 alleles. The
latter observations suggest that NOTCH1 activation in CLL
Figure 9.  Representative NICD1 staining in
angioimmunoblastic T cell lymphoma.  Left, intranodal
tissue, showing variable staining of resident cells. Right,
micrograph showing a sharp decrease in NICD1 staining in
extranodal (E) tumor cells as compared to nodal (N) tumor
cells, which are separated by the nodal capsule (C).
doi: 10.1371/journal.pone.0067306.g009
Table 3. NICD1 staining in peripheral T cell lymphomas.
Tumor Type (N=55 Total Cases) NICD1 Staining Results
Angioimmunoblastic lymphoma (N=14) 86% positive (N=12; all subsetpositive)
Peripheral T cell lymphoma, NOS (N=12) 42% positive (N=5; all subsetpositive)
Cutaneous T cell lymphoma (N=12) 17% positive (N=2; all subsetpositive)
Anaplastic large cell lymphoma (ALCL, N=7) 14% positive (N=1; subset positive,ALK+ tumor)
 86% negative (N=6, 1 ALK+ tumor,5 ALK-tumors)
Adult T cell leukemia/lymphoma (N=5) 20% positive (N=1; diffuselypositive)
EBV+ T/NK extranodal lymphoma (N=4) 0% positive
Subcutaneous paniculitis-like T cell
lymphoma (N=1) 0% positive
NOS, not otherwise specified; ALK, anaplastic lymphoma kinase; EBV, Epstein–
Barr virus; NK, natural killer cell
Diffusely positive, ≥80% of cells positive; subset positive, ≤80% of cells positive
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may be largely ligand-mediated; if true, this would have
significant therapeutic implications, since ligand-specific
blocking antibodies with antitumor activity have been
developed [53,54]. Our observations point to the need for
further work on nodal factors that trigger NOTCH1 activation in
CLL cells and potentially in other tumors as well. By contrast,
while our identification of a novel activating NOTCH1 deletion
in the mantle cell lymphoma cell line REC-1 and prior
identification of NOTCH1 mutations in primary cases of mantle
cell lymphoma [7] clearly indicate an oncogenic role for
NOTCH1, our failure to detect NOTCH1 activation or NOTCH1
mutations in 53 well characterized mantle cell lymphomas
suggests that involvement of NOTCH1 in this disease is rare.
NOTCH1 has an important role in regulating the
differentiation and function of diverse peripheral T cell subsets
[55], but its role in peripheral T cell lymphomas is largely
unknown. Detection of NICD1 in a substantial subset of
peripheral T cell lymphomas suggest that Notch antagonists
merit study as potential treatments for these tumors, which
have poor outcomes with current therapies.
NOTCH1 is a double-edged sword with respect to
tumorigenesis, being capable of serving as a tumor suppressor
as well as an oncoprotein. Indeed, inhibition of notch signaling
in rodents with inhibitory antibodies directed against the Notch
ligand DLL4 leads to tumors in several organs that may be of
vascular origin [56], and conditional knockout of notch1 in
endothelial cells causes the appearance of vascular
proliferations in the liver [19,20], suggesting that NOTCH1 is a
tumor suppressor in endothelium. However, we observed
ongoing NOTCH1 activation in a high fraction of human
angiosarcomas, particularly in those that are well differentiated.
Thus, while loss of NOTCH1 function may be associated with
progression of angiosarcoma, it may not be essential for its
genesis. These findings suggest that the role of NOTCH1 in
transformed endothelium cells merits additional study.
In addition to cancer cells, we observed widespread
activation of NOTCH1 in normal endothelial cells and variable
activation in mononuclear cells that may represent T cells,
macrophages or dendritic cells. Given that NOTCH1 signaling
has been implicated in a number of non-neoplastic
immunologic, inflammatory and vascular conditions [14,57], the
method described here should find widespread use in studying
NOTCH1 activation in a broad range of human disorders and
corresponding experimental models.
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